BharatBriefly
Read less. Ask more.

Intelligent News Feed

Loading…

Isomorphic Labs Raises $5 Billion in Series C Funding to Advance Drug Trials

· Technology · TechCrunch

Isomorphic Labs has raised $5 billion in a Series C funding round to advance its AI-designed drug candidates into clinical trials. The funding round was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and existing backers including Alphabet divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The platform builds on DeepMind's AlphaFold protein-folding AI model and has yielded positive preclinical results in oncology and immunology. The company has previously struck research deals with pharmaceutical firms including Eli Lilly, Novartis, and Johnson & Johnson. The new capital follows a $2.1 billion Series B round raised in May and will support further development of its drug-design engine and expansion into new therapeutic areas.

Why it matters

The $5 billion funding round provides Isomorphic Labs with substantial capital to transition its AI-designed molecules from preclinical research into human clinical trials, marking a major test for artificial intelligence in pharmaceutical drug discovery.

Read the original report — TechCrunch

Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.